Carlos Escande, Karina Cal, Alejandro Leyva, Jorge Rodriguez-Duarte, Santiago Ruiz, Leonardo Santos, Lucía Colella, Mariana Ingold, Cecilia Vilaseca, German Galliussi, Lucía Ziegler, Thais Peclat, Mariana Bresque, Rachel Handy, Rachel King, Larisa Menezes Dos Reis, Camila Espasandin, Peter Breining, Rosina Dapueto, Andres Lopez, Katie Thompson, Guillermo Agorrody, Evan DeVallance, Ethan Meadows, Sara Lewis, Gabriele Santana Barbosa, Leonardo Osbourne Lai de Souza, Marina Santos Chichierchio, Valeria Valez, Adrian Aicardo, Paola Contreras, Mikkel Vendelbo, Steen Jakobsen, Andres Kamaid, Williams Porcal, Aldo Calliari, Jose Verdes, Jianhai Du, Yekai Wang, John Hollander, Thomas White, Rafael Radi, Guillermo Moyna, Celia Quijano, Robert O'Doherty, Pedro Manoel Moraes-Vieira, Graham Holloway, Roberta Leonardi, Marcelo Mori, Juliana Camacho-Pereira, Eric Kelley, Rosario Duran, Gloria Lopez, Carlos Batthyany, Eduardo Chini
Obesity-related type II diabetes (diabesity) has increased global morbidity and mortality dramatically. Previously, the ancient drug salicylate demonstrated promise for the treatment of type II diabetes, but its clinical use was precluded due to high dose requirements. In this study, we present a nitroalkene derivative of salicylate, 5-(2-nitroethenyl)salicylic acid (SANA), a molecule with unprecedented beneficial effects in diet-induced obesity (DIO). SANA reduces DIO, liver steatosis and insulin resistance at doses up to 40 times lower than salicylate...
July 12, 2023: Research Square